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Erythrocyte Na,K pump activity and arterial hypertension in uremic
dialyzed patients. We have evaluated in 26 uremic patients [21 on
hemodialysis, 5 on continuous ambulatory peritoneal dialysis (CAPD)],
11 normotensive, and 15 hypertensive (MAP> 110 mm Hg) patients the
following properties: a) erythrocyte (RBC) Na concentration [Na] nd
ouabain-sensitive and -resistant Na effiuxes; b) the effect of uremic sera
on ouabain-sensitive Na efflux in normal RBC; c) serum digoxin-like
immunoreactivity; d) cardiac index and total peripheral resistance. In
19 healthy subjects a) and c) were also evaluated. RBC Na,K pump
activity was lower in uremic patients than in normal subjects (P <
0.0005), and lower in hypertensive (P < 0.02) than in normotensive
patients. Serum from uremic patients inhibited ouabain-sensitive Na
efflux in normal RBC, the inhibition being correlated with both the rate
constant for ouabain-sensitive Na efflux (r =
—0.67; P < 0.005) and
[Na1] (r = 0.43; P < 0.05) of RBC of patients from whom the serum was
obtained. Inhibition of ouabain-sensitive Na efflux was significantly
higher with serum from hypertensive than from normotensive patients(P < 0.05). Serum digoxin-like immunoreactivity was present in all
uremic patients (0.402 0.054 ng/ml in normotensive and 0.428 0.040
ng/ml in hypertensive, P = ns), while it was not detectable in normal
subjects. Hypertensive patients had peripheral resistance significantly
higher than normotensive (P < 0.05), while cardiac index was similar in
both groups. A strong inverse correlation was found between the rate
constant for ouabain-sensitive Na efliux in RBC and total peripheral
resistance (r =
—0.76; P < 0.0001). In conclusion: 1) Hypertensive
uremic dialyzed patients have lower erythrocyte Na,K pump activity as
compared with normotensive, and higher levels of a specific circulating
Na,K pump inhibitor; 2) reduced sodium transport by Na,K pump is
strongly correlated with increased total peripheral resistance, thus
suggesting a role in the pathogenesis of arterial hypertension in patients
with chronic uremia undergoing hemodialysis or CAPD; 3) a digoxin-
like jmmunoreactjve material is detectable in uremic sera, but it does
not have a close relationship to Na,K pump inhibitor.
Since the original reports by Welt and colleagues [1, 2], some
authors have confirmed a derangement of Na,K pump activity
in erythrocytes (RBC) from patients with chronic renal failure
[3—13], while others obtained conflicting results [14—16]. Abnor-
malities of cation composition and transport were also found in
leucocytes [17], skeletal muscle [18], intestine [19], brain [20],
and heart muscle [21] of uremic animals or patients, suggesting
a widespread defect. This abnormality of erythrocyte Na,K
pump was reversed by several weeks of hemodialysis [2], and
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was reproduced in normal erythrocytes incubated in vitro with
uremic plasma [6, 9, 11, 12, 22].
These observations suggested the presence in uremic plasma
of a sodium pump inhibitor(s), which has been related to a
digoxin-like substance(s) [23, 24].
More recently it has been reported that hemodialysis [11, 25,
26] and peritoneal dialysis [13] were able to acutely stimulate
Na,K pump activity in erythrocytes, and to reduce the plasma
concentration of the digoxin-like factor(s) [24]; moreover, the
amount of stimulation of the Na,K pump was correlated in three
studies to the degree of volume removal during hemodialysis
[11, 25, 26]. Thus it has been speculated that the trigger for the
release of this Na,K pump inhibitor is hypervolemia: predialy-
sis fluid retention could stimulate the secretion of this sub-
stance, which is then lowered by volume removal during
hemodialysis.
The pathophysiological relevance of the Na,K pump suppres-
sion in uremic patients is currently unknown. Inhibition of
Na,K ATPase in the kidney may have a finalistic role, by
reducing sodium reabsorption, in maintaining fluid balance
despite the marked reduction of glomerular filtration rate [27,
28]. A defect in sodium transport could be implicated in the
genesis of arterial hypertension, which is common in these
patients, and often related to fluid overload [29].
In fact it has been reported that, as a consequence of Na,K
pump inhibition in vascular smooth muscle cells, more sodium
is accumulated inside the cells and is paralleled by calcium
influx, enhancing both basal vascular tone and responsiveness
to vasoconstrictor stimuli [30]. Na,K pump inhibition increases
the noradrenaline output from peripheral adrenergic neurons
[31, 32].
The aims of this study are to further investigate the Na,K
pump status in erythrocytes from uremic patients undergoing
regular hemodialysis or peritoneal dialysis, and to explore its
relationship with arterial pressure and systemic hemodynamics.
Methods
Subjects
Twenty-six uremic patients, 21 on hemodialysis and five on
continuous ambulatory peritoneal dialysis (CAPD), were inves-
tigated. Their clinical characteristics are depicted in Table 1.
Residual renal function was absent in all patients. Fifteen
patients were hypertensive (mean arterial pressure > 110 mm
692 Boero et a!: Erythrocyie Na K-A TPase and hypertension
Table 1. Selected clinical and hematological data of uremic patients
Normotensive Hypertensive P value
Cases 11 l5 NS
Males/females 3/8 9/6 NS
Age years 61 4 52 4 NS
Dialytic age months 38 10 37 8 NS
HD/CAPD 9/2 12/3 NS
Body surface area m2 1.72 0.07 1.63 0,05 NS
Actual body weight 72.6 4.3 63.5 3.9 NS
Estimated dry weight 69.4 0.9 59.5 3.6 NS
Absolute difference 3.2 0.7 4.0 0.7 NS
Percent difference 4.5 0.9 6.6 0.9 NS
Hematocrit % 28 2 26 I NS
Hemoglobin gIdi 8.6 0.5 8.3 0.4 NS
Urea mg/dl 172 10 176 11 NS
Creatinine mg/d! 11.4 0.6 11.7 0.6 NS
Sodium mmol/!iter 136 1 138 I NS
Potassium mmollliter 5.8 0.2 5.8 0.2 NS
Bicarbonate mmol/liter 20.1 0.9 20.6 0.8 NS
Hg). No patient was taking digitalis. Antihypertensive medica-
tions were withdrawn at least one week prior to the study.
There were no signs of heart failure or extreme atherosclerosis,
and no patient was anephric.
Chronic renal failure was due to glomerulonephritis (4 cases),
interstitial nephritis (10), nephroangiosclerosis (8), polycystic
kidney (2), unknown disease (2), without diff'erences in distri-
bution between normotensive and hypertensive patients.
Hemodialysis patients were dialyzed four hours, three times
weekly using hollow fiber or plate (0.8 to 1.3 m2) Cuprophan'
disposable dialyzers. All patients were on bicarbonate hemodi-
alysis (dialysate composition in mmol/liter: Na 138, K 2, Ca
1.75, Mg 0.5, Cl 108.5, CH3COO 5, HCO 31, glucose 5.55).
CAPD schedule consisted of three to four exchanges per day
using two liter bags containing a dialysate composition in
mmoi/liter of Na 137, Ca 1.75, Mg 0.75, Cl 102, lactate 35 and
variable glucose concentration.
Nineteen normal subjects (10 males, 9 females), mean age 33
1 years, served as controls for erythrocyte cation transport
study.
All subjects agreed to take part in the study after its aims and
methods had been explained to them.
Hemodynamic parameters
The study was carried out in a quiet room, after 20 minutes of
bed rest, just before commencement of dialysis in hemodialysis
patients and after having voided peritoneal fluid or CAPD
cases.
Arterial blood pressure was measured by the same observer
using a standard sphyginomanometer, with a cuff of appropriate
size for each case; mean arterial pressure (MAP) was calculated
as one-third of the pulse pressure plus the diastolic pressure.
Values represent the mean of three readings.
Hemodynamic parameters were noninvasively gathered by
means of an electrical bioimpedance monitor (NCCOM3; Bio-
Med, Medical Manufacturing Ltd, Irvine, CA, USA). This
device detects the changes in transthoracic electrical imped-
ance associated with the cardiac cycle, and allows a simulta-
neous beat to beat evaluation of: heart rate, left ventricular
stroke volume, and cardiac output. This technique has been
applied and validated in the investigation of cardiac output in
several clinical and experimental conditions [33—361.
Registration of these parameters was made with the patient
supine, and protracted for several minutes until stabilization;
then all reliable values corresponding to 300 heart cycles were
registered and averaged.
Stroke index and cardiac index (CI) were calculated dividing
stroke volume and cardiac output by body surface area. Total
peripheral resistance index (TPRI) was calculated according to
the following formula:
MAP (mm Hg)TPR dynes . sec/(cm5 . m2) = . x 80CI l(min m2)
Erythrocyte sodium concentration and fluxes
Blood was drawn from the arterio-venous fistula, before the
session for hemodialysis patients and during the morning bag
exchange for CAPD patients, collected into heparinized tubes,
and immediately processed. Intra-erythrocyte Na concentra-
tion ([Na1]) was evaluated by hemolyzing in deionized water a
fixed volume of erythrocytes (100 pA), which had been washed
three times with 110 mmol/liter MgCl2 solution at 4°C. The Na
concentration of the hemolysate was measured on a Perkin
Elmer model 2380 atomic absorption spectrophotometer (Nor-
walk, Connecticut, USA) and was expressed as mmol/liter of
packed red cells. RBC Na efflux mediated by Na,K pump was
estimated in fresh cells according to Garay et a! [37], as
previously described [12, 261. The washed erythrocytes were
resuspended in a cold magnesium-sucrose medium (mmol/liter):
75 MgCI2, 85 sucrose, 10 MOPS-Tris (pH 7.4 at 37°C) and 10
glucose, to a hematocrit of 20 to 25%. A portion of the cell
suspension was added (final hematocrit 4 to 5%) to different
cold solutions containing buffered magnesium-sucrose plus the
following additions (mmol/liter): (1) 2 KC1, (2) 0.1 ouabain.
Duplicate samples were taken at 0 and 30 minutes for medium
one and at 0 and 60 minutes for medium 2. After incubation
tubes were transferred in an ice bath for one minute and then
centrifuged at 1750 g for five minutes at 4°C. The supernatant
was carefully removed and the Na concentration was measured
by atomic absorption spectrophotometry. Sodium efflux was
taken as the difference between the Na content after incubation
and the baseline Na content. The Na,K pump activity was
calculated by subtracting Na efflux in the presence from that in
the absence of ouabain. The rate constants for ouabain-sen-
sitive and -resistant Na effluxes were calculated by dividing the
respective Na effluxes by the [Na1], and were expressed in hr'.
In vitro incubation of normal erythrocytes with uremic serum
We also investigated the effect on Na,K pump of the pre-
incubation before flux assay (3 hrs at 37°C in a water bath kept
constantly shaken at a hematocrit of about 30%) of RBC from
four normal subjects with serum from uremic patients, matched
for blood groups, and in their own serum as a control. After
incubation cells were washed with 110 mmol/liter MgCI2 as
above, and pump-mediated Na efflux was assessed as above.
Digoxin-like immunoreactivity in the serum (DL.IA)
This was evaluated by a commercially available fluorescence
polarization immunoassay (Abbot TDX, Abbot Laboratories,
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patients
Normotensive
N= 11
Hypertensive
N= 15 Pvalue
Intracellular Na 7.9 0.6 8.0 0.3 NS
concentration mmol/l cell
Ouabain-sensjtjve Na efflux 1896 86 1729 82 <0.05
p.mol/liter cell/hr
Rate constant for 0.245 0.011 0.217 0.007 <0.02
ouabain-sensjtjve
Na efflux hr'
Ouabain-resistant Na efflux 284 31 296 27 NS
p.mol/liter cell/hr
Rate constant for 0.035 0.003 0.036 0.003 NS
ouabain-resistant
Na efflux hr'
North Chicago, Illinois USA), highly specific for digoxin and its
metabolites, and expressed in digoxin equivalents (ng/ml).
Other measurements
Plasma sodium and potassium were measured by flame
photometry, and urea, creatinine, bicarbonate, hemoglobin and
hematocrit according to standard autoanalyzer techniques.
Data are expressed as means SEM (standard error of the
mean). For statistical evaluation, single regression analysis,
Student's I-test and the Mann Whitney U test were employed.
Results
Hemodynamic parameters
Arterial pressure was 131 7/75 4mm Hg in normotensive
and 180 6/105 3 mm Hg in hypertensive patients (P <
0.0005); heart rate was 74 4 and 79 3 beats/mm, respec-
tively (P = NS). Stroke index (38.8 6 and 37.3 4 mL1min m2,
respectively) and cardiac index (2.9 0.4 and 2.9 0.3
mI/mm . m, respectively) were similar in both groups, while
total peripheral resistance index was significantly higher in
hypertensive than in normotensive patients (4256 448 vs.
2123 418 dynes . sec/(cm5 . m2); P < 0.05).
Hypertensive patients were more fluid overloaded than nor-
motensive, even though the difference was not significant
(Table 1). Accordingly, ultrafiltration to the estimated dry
weight significantly reduced arterial pressure in hypertensive
patients from 180 6/105 3 mm Hg to 148 3/92 3, P <
0.01.
Erythrocyte sodium concentration and fluxes
Erythrocyte Na,K pump activity was significantly lower in
uremic patients than in normal subjects, both expressed as the
absolute ouabain-sensitive Na efflux (1799 61 vs. 2334 95
mol/liter cell/hr; P <0.0005), and as the rate constant (0.229
0.007 vs. 0.295 0.012 hr'; P < 0.0005), while intra-eryth-
rocyte Na concentration was similar in both groups (8.0 0.2
vs. 8.1 0.4 mniol/liter cell; P = NS).
Erythrocyte ouabain-resistant Na efflux was significantly
lower in uremic patients than in controls, both expressed as the
absolute efflux (291 20 vs. 419 96 mol/liter cell/hr; P <
0.025), and as the rate constant (0.036 0.002vs. 0.052 0.007
hr P < 0.01). This behavior persisted when controls where
:1'
:•
Uremic patients
Normotensive Hypertensive
N=11 N=15
Fig. 1. Rate constant for ouabain-sensitive Na efflux in erythrocytes
from normal subjects and uremic patients. Individual data are shown;
(normal subjects vs. normotensive and hypertensive uremic patients: P
< 0.005; normotensive vs. hypertensive uremic patients: P < 0.02).
compared separately with normotensive and hypertensive ure-
mic patients. Hypertensive uremic patients had a mean eryth-
rocyte Na,K pump activity significantly lower than normoten-
sive patients, while intra-erythrocyte Na concentration and
ouabain-resistant Na efflux were similar in both groups (Table
2, Fig. 1).
We found significant correlations between the rate constant
for ouabain-sensitive Na efflux in erythrocytes from uremic
patients and systolic pressure (r = —0.46; P < 0.025), diastolic
pressure (r = —0.48; P < 0.025), mean arterial pressure (r =
—0.48; P < 0.025), stroke index (r = 0.56; P < 0.025), cardiac
index (r = 0.54; P < 0.025) and total peripheral resistance (r =
—0.76; P < 0.0001; Fig. 2). The latter correlation was present
also even when hypertensive (r =
—0.78; N = 15; P < 0.005)
and normotensive patients (r =
—0.70; N 11; P <0.025) were
considered separately.
In vitro incubation of normal erythrocyles with uremic serum
Preincubation of erythrocytes from normal subjects with
serum from uremic patients resulted in an inhibition of Na,K
pump activity in all cases (Table 3).
There were significant correlations between the percent changes
in ouabain-sensitive Na efflux or normal erythrocytes after
pre-incubation with uremic serum in vitro and both the rate
Table 2. Intra-erythrocyte Na concentration and fluxes in uremic , 0.40>
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Fig. 2. Correlation between the rate constan (for ouabain-sensitive Na
efflux in erythrocytes and total peripheral resistance in uremic patients.
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Table 3. Effects of incubation of normal erythrocytes in their own
serum and in serum from uremic patients on ouabain-sensitive Na
cifiux (absolute values are expressed as itmol/Iiter RBC/hr)
Donor Donor's
number serum tJremic serum Absolute A % A
1 2518 B.N. 2053 —473 —18.8
L.R. 2176 —342 —13.6
P.M. 2217 —301 —11.9
R.S. 2100 —418 —16.6
V.S. 2237 —281 —11.1
B.M. 2213 —305 —12.1
C.M. 2239 —279 —11.1
D.R. 2050 —468 —18.6
L.V. 2193 —325 —12.9
M.P. 1958 —560 —22.2
2 1519 B.C. 1224 —295 —19.4
B.S. 1319 —200 —13.2
B.D. 1367 —152 —10.0
CS. 1185 —334 —21.9
S.G. 1481 —38 —2.5
3 1863 A.A. 1749 —114 —6.1
B.S. 1779 —84 —4.5
B.A. 1759 —104 —5.6
C.O. 1627 —236 —12.7
O.G. 1537 —326 —17.5
4 2142 C.G. 1764 —378 —17.6
M.M. 1769 —373 —17.4
M.B. 1838 —304 —14.2
N.M. 1880 —262 —12.2
R.M. 1771 —371 —17.3
R.E. 1887 —255 —11.9
constant for ouabain-sensitive Na efflux (r
—0.67; P C 0.005)
and [Na1] (r = 0.43; P C 0.05) of erythrocytes of patients from
whom the serum was obtained.
The inhibition of ouabain-sensitive Na efflux was significantly
higher with serum from hypertensive patients than from
normotensive (—15.0 1.4 vs. —11.8 1.3%; P C 0.05).
Accordingly we have found a significant correlation between
the inhibition of ouabain-sensitive Na efflux induced by uremic
serum and total peripheral resistance of patients from whom the
serum was obtained (r = 0.54; P C 0,005).
Serum digoxin-like immunoreaclivity
Serum digoxin-like immunoreactivity was present in all
uremic patients (0.402 0.054 ng/ml in normotensive and 0.428
0.040 ng/ml in hypertensive, P NS), while it was not
detectable in normal subjects.
No consistent relationship emerged between DLIA and Na,K
pump activity in patients' erythrocytes or with the inhibitory
effect of uremic serum on ouabain-sensitive Na efflux in normal
erythrocytes. Similarly, no correlation was found between
DLIA and hemodynamic parameters.
There were no differences in the various parameters between
males and females, and between patients treated with hemodi-
alysis or peritoneal dialysis.
Discussion
Arterial hypertension in end-stage renal failure is mainly due
to increased peripheral resistance [38—41], but the pathogenesis
of vasoconstriction is still perplexing [29].
Assuming that erythrocytes are representative of the sodium
pump status even in target cells, like vascular smooth muscle
cells and sympathetic neurons, our data support the hypothesis
that the alteration in Na,K pump activity may influence vascu-
lar tone in uremic patients.
In fact our hypertensive patients had erythrocyte Na,K pump
activity significantly lower than normotensive patients, and a
strong and highly significant inverse relationship may be found
between the rate constant for ouabain-sensitive Na efliux in
their erythrocytes and total peripheral resistance. To our
knowledge such a correlation has been hypothesized but never
previously demonstrated,
These data are in agreement with those reported by Brod et al
[10], who found a significant inverse correlation between the
ouabain-sensitive 42K influx in erythrocytes (which is an
estimate of the Na,K pump activity) and mean arterial pressure
in a group of subjects, including patients with chronic renal
failure.
Conversely, our data are at variance with those recently
reported by Engelhardt et al [42]; they found increased rather
than decreased Na,K pump activity in erythrocytes from hyper-
tensive uremic patients on hemodialysis as compared with
those from normotensive patients. Flowever, they used a dif-
ferent technique to estimate Na,K pump activity, and their
hypertensive patients received anti-hypertensive drugs during
the study. Thus, methodological differences might explain the
conflicting results.
Examination of the hemodynamic determinants of the calcu-
lated total peripheral resistance shows significant correlations
between the rate constant for erythrocyte ouabain-sensitive Na
effiux and mean arterial pressure (r =
—0.48; P C 0.025),
cardiac index (r 0.54; P C 0.005) and stroke index (r = 0.56;
P C 0.005).
The reduced stroke index in patients with lower erythrocyte
Na,K pump activity could theoretically reflect an increase in
afterload and/or in venous resistance, related to an enhanced
vascular tone.
Regarding the cause of the Na,K pump defect in erythrocytes
from uremic patients, our data confirm the existence of a
circulating inhibitor(s) [6, Il, 12, 22].
This substance behaves like the natriuretic hormone which de
Wardener and MacGregor have hypothesized to play a role in
the pathogenesis of vasoconstriction following volume expan-
sion in essential hypertension [43]. In fact the Na,K pump
inhibitory activity of uremic serum was significantly higher in
sera from hypertensive than from normotensive patients and
correlated with vascular peripheral resistance, Moreover, hy-
pertensive patients were more fluid overloaded than normoten-
sive, and ultrafiltration significantly reduced their arterial pres-
sure, confirming the volume-dependent nature of hypertension.
The chemical structure of the uremic Na,K pump inhibitor is
unknown: this substance has been identified by some authors
with a digoxin-like substance, able to cross-react with antidi-
goxin antibodies [23, 24, 44]. We were also able to detect a
significant digoxin-like immunoreactivity in sera from our pa-
tients; however, no consistent relationship emerged between
DLIA and Na,K pump activity in patients' erythrocytes or with
the inhibitory effect of uremic serum on ouabain-sensitive Na
eluiux in normal erythrocytes; similarly no difference in DLIA
was found between normotensive and hypertensive patients.
Hence immunoassay for digoxin may not represent a useful tool
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to determine the endogenous inhibitor of Na,K ATPase in
uremic serum.
Discrepancies between Na,K ATPase inhibitory material and
DLIA have also been reported by Kramer et al [231, who were
also unable to found a correlation between DLIA and blood
pressure.
Interestingly, a recent study [45] has shown that one of three
fractions of Na,K ATPase inhibitory activity, which shows
ouabain-displacing activity and was separated from human
plasma by HPLC, did not show cross reactivity against antidi-
goxin antibodies. Moreover, Tamura and colleagues reported
that linoleic acid and oleic acid [46] and lysophosphatidylcho-
line gamma-stearoyl have a Na,K ATPase inhibitory effect
under volume expanded conditions [47].
It is of note that Bleiberg et a! [48] reported erythrocyte and
plasma lipid abnormalities in patients with terminal renal insuf-
ficiency, including an increase of plasma phospholipids, which
could play a role in the altered Na,K pump function.
In conclusion, the main findings of this study are: 1) hyper-
tensive uremic dialyzed patients have lower erythrocyte Na,K
pump activity as compared with normotensive, and higher
levels of a specific circulating Na,K pump inhibitor; 2) reduced
sodium transport by Na,K pump is closely correlated with
increased total peripheral resistance, thus suggesting a role in
the pathogenesis of arterial hypertension in patients with chron-
ic uremia undergoing hemodialysis or CAPD; and 3) a digoxin-
like immunoreactive material is detectable in uremic serum, but
it does not have a close relationship to the Na,K pump
inhibitor.
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